NCI-Standard FOR PDF

50. Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol 2007;25(25):3991-4008. 51. Keefe DL. Anthracycline-induced cardiomyopathy. SeminOncol 2001;28(4 Suppl 12):2-7. 52. Dorr RT, Von-Hoff DD. Cancer chemotherapy handbook. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 459-468. 53. Siderov J, Prasad P, De Boer R, et al. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002;86(1):12-13. 54. Siderov J, Zalcberg J. Safe administration of oral etoposide after hypersensitivity reaction to intravenous etoposide. Anticancer Drugs 1994;5(5):602-3. 55. Dorr RT, Von-Hoff DD. Cancer Chemotherapy Handbook. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 27-28,123. 56. Petrelli N, Douglass HD, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1991;7(10):1419-1426. 57. Chansky K, Benedette J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal cancer. Cancer 2005;103(6):1165-71. 58. Petrelli N, Douglass HD, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1991;7(10):1419-1426. 59. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol 2005;23(30): 7685-7696. 60. Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1989;111(8):688-689. 61. Fabian CJ, Molina R, Slavik M, et al. Pyridoxine therapy for palmar-planter erythrodysesthesia associated with continuous 5- fluorouracil infusion. Invest New Drugs 1990;8(1):57-63 62. Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. JOCP 1994;12(8):1535-40. 63. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic, and phase I studies of gemcitabine. SemOnc 1997;24(2 Suppl 7):S7-2-S7-7. 64. Burris HA,3rd, Hainsworth JD, Erland JB, et al. Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer. SemOnc 2000;27(1 Suppl 2):9-13. 65. Colomer R, Llombart A, Lluch A, et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial. SemOnc 2000;27(1 Suppl 2):20-4. 66. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. JOCP 2000;18(17):3068-77. สถาบันมะเร็งแห่งชาติ กรมการแพทย์ กระทรวงสาธารณสุข 341

67. Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. JOCP 2000;18(9):1921-7. 68. Veltkamp SA, Beijnen JH, Schellens JHM. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist 2008;13(3):261-276. 69. Felici A, Di Segni S, Milella M, et al. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function. Clin Pharmacokinet 2009;48(2):131-141. 70. Aronoff GR, Bennett WM, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing guidelines for adults and children. 5th ed. Philadelphia, Pennsylvania: American College of Physicians; 2007. p. 100. 71. Brunello A, Basso U, Rossi E, et al. Ifosfamide-related encephalopathy in elderly patients: report of five cases and review of the literature. Drugs Aging 2007;24(11):967-973. 72. Qin D, Ma J, Xiao J, et al. Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents. Am J Clin Oncol 1997;20(3):263-5. 73. Joerger M, Huitema ADR, van den Bongard HJGD, et al. Determinants of the elimination of methotrexate and 7-hydroxymethotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2005;62(1):71-80. 74. Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978;41(1):36-51. 75. Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004;100(10):2222-32. 76. Dorr RT, Von-Hoff DD. Cancer chemotherapy handbook. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 27-28,123. 77. Yan TD, Deraco M, Baratti D, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience. Journal of Clinical Oncology 2009;27(36):6237-6242. 78. Tolley DA, Hargreave TB, Smith PH, et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J (Clin Res Ed) 1988;296(6639): 1759-1761 79. Wiseman LR, Adkins JC, Plosker GL, et al. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. Drugs & Aging 1999;14(6):459-75. 80. Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Critical Reviews in OncologyHematology 2000;35(2):75-93. 81. Cvitkovic E, Bekradda M. Oxaliplatin: a new therapeutic option in colorectal cancer. Seminars in Oncology 1999;26(6):647-62. 342 คู่มอื มาตรฐานการทำ� งานเกย่ี วกบั ยาเคมีบ�ำบดั และการดแู ลผ้ปู ว่ ยหลงั ได้รับยา

82. Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemotherapy & Pharmacology 2000;45(2):157-64. 83. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clinical Cancer Research 2000;6(4):1205-18. 84. Wilson RH, Lehky T, Thomas RR, et al. Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability. J Clin Oncol 2002;20(7):1767-1774. 85. DizonDS,SchwartzJ,RojanA,etal.Cross-sensitivitybetweenpaclitaxelanddocetaxelinawomen’scancers program. Gynecologic Oncology 2006(100):149-151. 86. Cresteil T, Monsarrat B, Dubois J, et al. Regioselective metabolism of taxoids by human cyp3A4 and 2C8: structure-activity relationship. Drug Metabolism and Disposition 2004;30(4):438-445. 87. Joerger M, Huitema ADR, Huizing MT, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol 2007;64(5):622-633. 88. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 2009(102):179-187. 89. Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. GyneOncol 2002;84:420-425. 90. Solimando DA, Jr. Cancer chemotherapy update: Updates of vinblastine and vincristine. Hosp Pharm 1997;32(4):475-82. 91. DeVita VT, Hellman S, Rosenberg SA. Cancer Principles & Practice of Oncology. 6th ed. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2010. p. 2640. 92. Joel S. The comparative clinical pharmacology of vincristine and vindesine. Cancer Treatment Reviews 1996;21(6)(Nov):513-25. 93. Dorr RT, Von-Hoff DD. Cancer chemotherapy handbook. In. 2nd ed. Norwalk, Connecticut: Appleton & Lange; 1994. p. 123. 94. Gassel WD, Gropp C, Havemann K. Acute allergic reaction due to vincristine sulfate. A case report. Oncology 1984;41(6):403- 5. 95. O’Marcaigh A, Betcher D. The Vinca Alkaloids. Pharmacology 1995;12(No 3):140-42. สถาบนั มะเรง็ แหง่ ชาติ กรมการแพทย์ กระทรวงสาธารณสุข 343